Nov 14 (Reuters) - Alkermes ( ALKS ) said on Friday it
is reviewing its options with advisers after Avadel
Pharmaceuticals ( AVDL ) disclosed it had received an
unsolicited takeover proposal from Danish pharmaceutical company
Lundbeck.
In October, Alkermes ( ALKS ) had said it will buy Avadel in a deal
worth up to $2.1 billion, aiming to enter the sleep medicine
market